Press Room - Sanofi US News

Menu

Media Room Menu

Month Year

Month Year

May 22, 2006

Sanofi-aventis announces steps to protect access to prescription drugs for low income medicare patients

S-A Continues to Advocate for Solutions to Assist Patients Inside the Medicare Part D Benefit - Takes Steps to Ensure Patient Safety
May 16, 2006

Star of the BatmanTM television series leads crusade for baby boomers to recognize importance of Benign Prostatic Hyperplasia (BPH)

Adam West and his wife team up to raise awareness of enlarged prostate due to BPH, the most common prostate problem in men
May 15, 2006

Yolanda King and African-American leaders across the country unite to fight stroke
May 5, 2006

First quarter of 2006: Sales growth of 9.6% on a reported basis and 4.9% on a comparable basis. 52.8% growth in adjusted EPS and 19.8% excluding selected items.
Apr 10, 2006

Appeals court rules in Sanofi-aventis’ favor in the U.S. LOVENOX® (enoxaparin sodium injection) patent infringement case
Mar 23, 2006

TAXOTERE® receives U.S. FDA approval for use in advanced stomach cancer

TAXOTERE(R)-based regimen demonstrates a 23% reduction in the risk of mortality in patients with advanced stomach cancer
Mar 20, 2006

Statement responding to recent media reports regarding appropriate use of AMBIEN® (zolpidem tartrate) CIV in the U.S.
Mar 12, 2006

New study furthers understanding of the role of dual antiplatelet therapy in the prevention of atherothrombotic events, including heart attack, stroke or cardiovascular death in broad population

Certain subgroups may benefit from dual therapy, for others it should be avoided
Feb 28, 2006

APIDRA® - a new rapid-acting insulin analog - is now available in the United States for hyperglycemia in adults with type 2 and type 1 diabetes

New prandial insulin with the OptiClik(R) delivery system can work with longer-acting insulins, such as basal insulin Lantus(R), providing a complementary approach to glucose control
Feb 24, 2006

Sanofi-aventis reports strong growth of 25.7% in 2005 adjusted EPS - Nearly 90% of synergies delivered by end 2005 - Dividend increased by 26.7%

Sanofi-aventis Reports Strong Growth of 25.7% in 2005 Adjusted EPS(1); Nearly 90% of synergies delivered by end 2005; Dividend increased by 26.7%
Feb 17, 2006

Sanofi-aventis received from the FDA an approvable letter for rimonabant for weight management and a non approvable letter for smoking cessation
Feb 14, 2006

The Journal of the American Medical Association publishes the RIO-North America study

Study Shows Rimonabant Maintains Improvements in Multiple Cardiometabolic Risk Factors for Up to Two Years
Feb 6, 2006

Sanofi Pasteur Delivers More H5N1 Vaccine for U.S. Government Pandemic Initiatives

New investigational doses include formulation with an adjuvant; Additional stockpile vaccine prepared
Feb 1, 2006

Sanofi Pasteur Experiences Unprecedented U.S. Demand for Influenza Vaccine for 2006-2007 Influenza Season
Jan 30, 2006

Dynamic growth in 2005 full-year consolidated net sales: up 9.3% on a comparable basis
Jan 18, 2006

FDA grants priority review to PLAVIX® (clopidogrel bisulfate) Supplemental New Drug Application (sNDA) for additional type of heart attack

Filing for STEMI Indication Also Submitted in Europe
Jan 13, 2006

Pfizer to purchase Sanofi-aventis rights to EXUBERA® in application of change of control clauses
Jan 4, 2006

Procter & Gamble Pharmaceuticals and Sanofi-aventis US LLC file lawsuit against Roche Pharmaceuticals and Glaxosmithkline

Lawsuit Alleges Advertising for Once-a-Month Osteoporosis Drug Misleads Physicians and Consumers
Dec 13, 2005

PLAVIX® (clopidogrel bisulfate) recommended as effective cardiovascular risk reduction treatment for patients with established Peripheral Arterial Disease (P.A.D.)
Dec 8, 2005

Interim analysis of phase III study shows TAXOTERE®-based regimens with HERCEPTIN® significantly improved disease free survival in women with early-stage HER2-positive breast cancer
Dec 6, 2005

New analysis ranks America’s worst cities for respiratory infections
Dec 2, 2005

FDA Grants Priority Review to Taxotere® for the Supplemental New Drug Application for Advanced Gastric Cancer
Nov 16, 2005

New England Journal of Medicine publishes the RIO-Lipids study
Nov 15, 2005

Study shows that intra-articular hyaluronate therapy HYALGAN® (sodium hyaluronate) is effective in treating chronic shoulder pain due to osteoarthritis
Nov 15, 2005

Analysis from several clinical studies show dronedarone appears to be consistently safe and effective in maintaining normal sinusal rhythm and ventricular rate control in patients with cardiac arrhythmia
Nov 8, 2005

Third quarter 2005: Adjusted EPS up 27.4%, net sales up 11.0% on a comparable basis - First 9 months of 2005: Adjusted EPS up 26.6%, net sales up 11.0% on a comparable basis
Nov 7, 2005

New data show long-term (52 week) use of ALVESCO® (ciclesonide) had a low incidence of oropharyngeal side effects in patients with mild-to-moderate asthma
Oct 20, 2005

EXUBERA® inhaled insulin improves blood sugar levels in adults with type 2 diabetes better than diabetes pills alone
Oct 7, 2005

AMBIEN CR™ now available in the US
Sep 29, 2005

Hearing date set on motion for preliminary injunction in ALLEGRA® (fexofenadine hcl) patent infringement case
Sep 29, 2005

Sanofi-aventis provides relief to hurricane victims
Sep 20, 2005

FDA accepts filed pre-market approval supplement to expand the indication for HYALGAN® (sodium hyaluronate) to include shoulder pain due to osteoarthritis
Sep 15, 2005

INTERIM ANALYSIS OF PHASE III STUDY SHOWS TAXOTERE® (docetaxel)- BASED CHEMOTHERAPY REGIMENS COMBINED WITH HERCEPTIN® (trastuzumab) SIGNIFICANTLY IMPROVED DISEASE FREE SURVIVAL IN EARLY-STAGE HER2-POSITIVE BREAST CANCER
Sep 14, 2005

Study Finds Alvesco® (ciclesonide) Did Not Affect HPA-Axis Function in Patients with Moderate-to-Severe Persistent Asthma
Sep 12, 2005

Sanofi-aventis Group enters agreement with Prasco Laboratories to market generic versions of ALLEGRA® (fexofenadine HCl)
Sep 8, 2005

FDA Advisory Committee recommends Approval of EXUBERA® for use in adults with type 1 and type 2 diabetes
Sep 6, 2005

AMBIEN CR™ (zolpidem tartrate extended-release tablets) CIV receives FDA Approval for the treatment of insomnia
Aug 31, 2005

Strong growth in 2005 first half adjusted EPS : up 26.1% at €2.22. Increase in full year adjusted EPS guidance. Positive phase IIb/III results for 6 products
Aug 18, 2005

Taxotere® Significantly Improves Survival Compared with paclitaxel In Women With Advanced Breast Cancer
Aug 15, 2005

The U.S. Food and Drug Administration approves ACTONEL® WITH CALCIUM
Aug 2, 2005

Sanofi-aventis Issues Strong Support for Voluntary “Guiding Principles” on DTC Advertising
Jul 27, 2005

ALLEGRA-D® 24 HOUR (fexofenadine HCl 180 mg/pseudoephedrine HCl 240 mg) EXTENDED RELEASE TABLETS NOW AVAILABLE FOR SEASONAL ALLERGY SUFFERERS
Jul 19, 2005

Strong net sales growth in the first half of 2005: 11.0% on a comparable basis - Further increase in market share in the second quarter
Jun 30, 2005

Sports Legend Tony Gwynn Teams up with Former Baseball Champions to Raise Awareness of Deep-Vein Thrombosis (DVT) in the National Educational Campaign, "DVT Blood Clots: Know The Stats. Know Your Risk.”
Jun 28, 2005

PANEL OF EXPERTS AGREE THAT BONE MINERAL DENSITY IS NO LONGER ENOUGH
Jun 23, 2005

RIMONABANT ACCEPTED FOR FILING BY THE FDA
Jun 14, 2005

Data presented at American Diabetes Association Scientific Sessions support Exubera® Efficacy and Safety Profile in Type 1 and Type 2 Diabetes
Jun 13, 2005

Lantus® Add-on to Oral Monotherapy Therapy Showed Improved Glycemic Control in Type 2 Diabetes Patients Compared to Oral Actos Add-on to Oral Therapy
Jun 13, 2005

Clinical Study Results Demonstrated Greater Flexibility With Mealtime Dosing of Apidra® When Compared to Regular Human Insulin
Jun 13, 2005

DATA PRESENTED AT ADA SHOWED THAT BASAL INSULIN THERAPY WITH LANTUS® ACHIEVED TARGET GLYCEMIC CONTROL IN POORLY CONTROLLED TYPE 2 DIABETES
Jun 12, 2005

Rimonabant study shows significant improvements in HbA1c and cardiometabolic risk factors in people with type 2 diabetes
Jun 8, 2005

Prospective Study Published in Diabetes Care Confirms Basal Therapy with Lantus® Improves Glycemic Control in Patients with Type 2 Diabetes Poorly Controlled on Prior Insulin Regimens
Jun 2, 2005

Landmark Taxotere® Study in Early Stage Breast Cancer Published in the New England Journal of Medicine
May 31, 2005

Sanofi-aventis Annual General Meeting
May 25, 2005

UROXATRAL® (alfuzosin HCl) STUDY SHOWS IMPROVEMENT UP TO TWO YEARS IN LOWER URINARY TRACT SYMPTOMS AND SEXUAL FUNCTION IN MEN WITH ENLARGED PROSTATES
May 24, 2005

New Study Demonstrates Clinical Efficacy of Telithromycin Superior to Standard First-Line Antibiotic Therapy for Treatment of Mild to Moderate Community-Acquired Pneumonia (CAP)
May 23, 2005

New Data Demonstrate Alvesco® (ciclesonide) Significantly Reduces Oral Corticosteroid Use in Patients with Severe, Persistent Asthma
May 15, 2005

Taxotere® Regimen Demonstrates Significant Survival Benefit In The Treatment Of Advanced Gastric Cancer
May 13, 2005

Sanofi-aventis 2005 first-quarter net sales
May 10, 2005

Rescheduling of the pre-trial order date in the United States Plavix® litigation
May 10, 2005

New Eloxatin® and Taxotere® research to be presented at the annual meeting of the American Society of Clinical Oncology (ASCO)
Apr 15, 2005

Sanofi-aventis affirms its commitment to Access to Medicines in the "Southern countries", with a policy of tiered drug prices geared to populations incomes
Apr 11, 2005

FDA issues approvable letter for AMBIEN CR™ (zolpidem tartrate extended release) C IV for the treatment of Insomnia
Apr 7, 2005

Sanofi-aventis Statement
Apr 1, 2005

Sanofi-aventis concludes €10 billion in medium-term credit agreements with its banks to refinance the Aventis acquisition financing entered into in April 2004
Mar 30, 2005

Rescheduling of the pre-trial order date in the United States Plavix® litigation
Mar 24, 2005

Sanofi-aventis joins the fight against tuberculosis in South Africa
Mar 22, 2005

New Data Demonstrate Alvesco® (ciclesonide) Has a Low Incidence of Mouth- and Throat- Related Side Effects in Pediatric Asthma Patients
Mar 22, 2005

New Data Demonstrate Alvesco® (ciclesonide) Significantly Improves Quality-of-Life for Patients with Mild-to-Moderate Asthma
Mar 22, 2005

Court grants Sanofi-aventis's request for Order of Prohibition in the Canadian Plavix® litigation
Mar 11, 2005

SANOFI-AVENTIS SUES NOVOPHARM FOR PATENT INFRINGEMENT IN CANADA
Mar 9, 2005

CLOPIDOGREL IMPROVED CORONARY PERFUSION AND REDUCED MORTALITY IN ACUTE HEART ATTACK
Mar 2, 2005

PFIZER AND THE SANOFI-AVENTIS GROUP SEEK APPROVAL TO MARKET EXUBERA® IN THE UNITED STATES
Mar 1, 2005

Sanofi-aventis 2004 Results
Feb 24, 2005

Creation of the sanofi-aventis European Works Council
Feb 24, 2005

First Pilot Study to Show Benefit Using Hyalgan® (sodium hyaluronate) in the Treatment of Osteoarthritis of the Ankle
Feb 23, 2005

Update of the Patent Litigation Schedule in the United States for Plavix®
Feb 18, 2005

Sanofi-aventis world solidarity day on behalf of South East Asia - January 25, 2005: "Sharing in solidarity"
Feb 17, 2005

Sanofi-aventis announces commercial availability of twice-yearly Eligard®
Feb 2, 2005

Sanofi-aventis receives FDA approval for new Eloxatin™ formulation
Jan 26, 2005

2004 pro forma combined net sales: up 10.0% on a comparable basis
Jan 25, 2005

Plavix® patent
Jan 25, 2005

Sanofi-aventis “Solidarity Day” offers additional aid, assistance to Southeast Asia “Sharing in solidarity”
Jan 19, 2005

The European Commission imposes a fine on certain MCAA producers
Jan 11, 2005

Taxotere® (docetaxel) receives 2 new European approvals for treatment of breast cancer
Jan 11, 2005

New Together Rx Access™ Card offers Americans with no prescription drug coverage savings at the pharmacy counter
Jan 10, 2005

Sanofi-aventis and Regeneron Pharmaceuticals reaffirm development commitment
Jan 10, 2005

Aventis Pasteur, the vaccine division of the sanofi-aventis Group, changes its name to sanofi Pasteur
Jan 6, 2005

Update of the patent litigation schedule in the United States for Plavix®
Jan 3, 2005

Sanofi-aventis provides Humanitarian Aid for South-East Asia

Show per page

Print
Email page
RSS

You are about to leave www.sanofi.us

If you wish to continue to this external website, click Proceed. It is provided for information only. Sanofi assumes no responsibility for the information presented on this website.